https://www.selleckchem.com/pr....oducts/direct-red-80
umulation in G1 and subG1 and limited progression to S phase, thus reducing effectiveness of PARP inhibition.Conclusions Niraparib effectively radiosensitizes HNSCCs with a greater benefit seen in HPV(-). HPV status also plays a role in response to MK-8776 or MK-1775 when combined with niraparib due to differences in DNA repair mechanisms. This study suggests that using cell cycle abrogators in combination with PARP inhibitors may be a beneficial treatment option in HNSCC, but also emphasizes the importance of HPV status when cons
Like
Comment
Share
